Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: PlayTheKing who wrote (10155)	7/11/2002 8:30:19 AM
From: TheBusDriver	Respond to of 14101

Thanks!

To: PlayTheKing who wrote (10155)	8/8/2002 10:41:35 AM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

PTK (and Villagers) What is your take on the YE financials? Revenues were Q1 96 (mostly Dioptic <gg>) Q2 344 Q3 51 Q4 524 Provalis was terminated June 14th. Any guess what the Q4 revenue break down is? Pennsaid 2001 sales total 513,000 Dioptic 2001 sales total 456,000 UK Caribbean Luxumbourge Dioptic = 456,000 OXO (would OXO register only one day of sales?) There was a pickup in Pennsaid sales later in the year because Q1, Q2 and Q3 had neglible Pennsaid sales. I doubt Q4 had any significant UK sales. That leaves Caribbean and Lux. I'm uncomfortable with the Sales & Marketing Expense. Q1 308 Q2 887 Q3 1132 Q4 1017 Q4 spanned Mar-May and there were no expectation of a HC approval then. So why spend $1mm plus in this area? Grunt. Selling and marketing expenses increased to $3.3 million in fiscal 2002 from $1.4 million in the prior fiscal year, reflecting the cost of recruiting and training medical representatives in anticipation of PENNSAID(R) regulatory approval in Canada. Other than that item, everything is as expected. Hope we see a return on OXO investment asap given the low level of cash resource and committments. The traditional route with a Partner would be a suggestion.